Nexentis Technologies Inc.
NXTS Nasdaq Pharmaceutical Preparations Financials FY2018βFY2025
What Nexentis Technologies Inc. does
No business description yet.
- Legal name
- Nexentis Technologies Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 31, 2026
- Accession Β· CIK
- 0001493152-26-014183
0001789192
Revenue and margins
Nexentis Technologies Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$3.8M in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Nexentis Technologies Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 588.1%.
Balance sheet
Cash, debt and the ratios that show how comfortably Nexentis Technologies Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $6.8M | $5.7M | $4.4M | $2.2M | $4.1M |
| Debt incl. finance leases | $0.0M | β | β | β | $0.7M |
| Debt / equity | 0.0x | β | β | β | 0.0x |
| Current ratio | 7.8x | 8.8x | 7.0x | 3.9x | 4.2x |
| Quick ratio | 7.7x | 8.7x | 6.9x | 3.8x | 4.2x |
| Total assets | $7.6M | $6.5M | $7.2M | $5.5M | $20.4M |
| Total liabilities | $1.2M | $0.8M | $0.8M | $0.9M | $4.7M |
| Shareholders' equity | $6.5M | $5.8M | $6.5M | $4.7M | $16.0M |
| Net debt (β = net cash) | β$6.7M | β | β | β | β$3.3M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 8 | 5 / 8 | 4 / 9 | 4 / 8 | 2 / 8 | 3 / 8 | 3 / 7 |
| Accruals ratio | 17.4% | β95.4% | β117.5% | β17.1% | β9.1% | β47.9% | β27.9% | β1.5% |
| Altman Z'' | β35.29 | β74.27 | β74.56 | β0.31 | β3.74 | β7.34 | β15.99 | β2.48 |
8 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0.4M | $0.2M | $0.2M | $0.4M | $0.4M | $0.3M | $0.2M | $0.0M |
| Net interest income | β | β | β | β | β$0.0M | β$0.1M | β$0.1M | $0.0M |
| Provision for credit losses | β$0.1M | $0.0M | $0.2M | $0.1M | β | β | β | β |
| Gross profit | $0.3M | $0.0M | $0.2M | $0.3M | $0.2M | $0.2M | $0.0M | β |
| Research and development | $0.4M | $0.6M | $0.4M | $0.5M | $0.8M | $1.9M | $0.4M | $0.2M |
| Operating income | β$0.5M | β$1.9M | β$1.3M | β$4.7M | β$5.8M | β$7.6M | β$3.3M | β$4.2M |
| Interest expense | β | β | β | β | β | β | $0.0M | β |
| Pretax income | β | β | β | β | β | β | β$4.3M | β$3.6M |
| Income tax | β | β | β | β | β | β | β | β$0.0M |
| Net income | β$0.4M | β$2.0M | β$1.6M | β$4.8M | β$5.7M | β$6.5M | β$5.2M | β$4.0M |
| Diluted EPS | β$0.05 | β$1.38 | β$1.05 | β$2.06 | $10.85 | β$5.43 | β$27.74 | β$8.61 |
| Diluted shares | β | β | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||
| Cash from operations | β$0.5M | β$1.2M | β$0.8M | β$4.1M | β$5.1M | β$3.2M | β$3.4M | β$3.8M |
| Capital expenditure | $0.0M | $0.0M | β | $0.1M | $0.1M | β | β | $0.0M |
| Free cash flow | β$0.5M | β$1.3M | β | β$4.2M | β$5.1M | β | β | β$3.8M |
| Depreciation and amortization | $0.1M | $0.0M | $0.0M | $0.1M | $0.1M | $0.0M | $0.0M | $0.1M |
| Stock-based compensation | $0.1M | $0.4M | $0.5M | $0.2M | $0.1M | $0.0M | $0.0M | $0.1M |
| Balance sheet | ||||||||
| Cash and short-term investments | $0.4M | $0.3M | $0.2M | $6.8M | $5.7M | $4.4M | $2.2M | $4.1M |
| Total debt | $0.1M | $0.0M | $0.0M | $0.0M | β | β | β | $0.7M |
| Current assets | $0.7M | $0.4M | $0.5M | $7.2M | $6.3M | $5.5M | $3.5M | $6.0M |
| Current liabilities | $0.5M | $0.6M | $0.8M | $0.9M | $0.7M | $0.8M | $0.9M | $1.4M |
| Inventory | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.0M | β |
| Property and equipment, net | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M | $0.0M |
| Goodwill | β | β | β | β | β | β | β | $6.3M |
| Intangible assets | β | β | β | β | β | β | β | $4.4M |
| Total assets | $0.9M | $0.7M | $0.7M | $7.6M | $6.5M | $7.2M | $5.5M | $20.4M |
| Total liabilities | $0.6M | $1.1M | $1.2M | $1.2M | $0.8M | $0.8M | $0.9M | $4.7M |
| Shareholders' equity | $0.2M | β$0.4M | β$0.4M | $6.5M | $5.8M | $6.5M | $4.7M | $16.0M |
| Margins | ||||||||
| Gross margin | 74.0% | 17.8% | 81.3% | 69.0% | 59.8% | 79.0% | 21.4% | β |
| Operating margin | β121.6% | β1,098.6% | β580.8% | β1,073.6% | β1,477.1% | β2,877.0% | β1,563.3% | β |
| EBITDA margin | β103.9% | β1,083.0% | β561.4% | β1,060.6% | β1,463.2% | β2,869.0% | β1,554.8% | β |
| Net margin | β83.7% | β1,121.4% | β685.8% | β1,100.3% | β1,456.8% | β2,476.1% | β2,472.9% | β |
| FCF margin | β119.3% | β721.3% | β | β954.3% | β1,306.8% | β | β | β |
| Net interest share of revenue | β | β | β | β | β8.6% | β25.1% | β26.2% | β |
| Returns | ||||||||
| Return on capital | β | β | β | β | β | β | β | β26.4% |
| Return on capital employed | β138.1% | β4,722.0% | 1,382.5% | β70.6% | β100.7% | β117.2% | β71.8% | β22.3% |
| Return on equity | β163.6% | β | β | β159.4% | β93.1% | β105.8% | β92.5% | β38.6% |
| Return on assets | β41.5% | β258.7% | β235.6% | β116.4% | β81.5% | β95.0% | β81.7% | β31.0% |
| Return on tangible equity | β163.6% | β | β | β74.4% | β98.2% | β100.6% | β109.3% | β75.7% |
| Growth | ||||||||
| Revenue growth | β | β58.8% | 32.1% | 88.6% | β10.1% | β33.1% | β20.3% | β100.0% |
| EPS growth | β | β | β | β | β | β150.0% | β | β |
| Share count change | β | β | β | 54.2% | β77.4% | 127.0% | β84.4% | 588.1% |
| Financial health | ||||||||
| Debt / equity | 0.4x | β | β | 0.0x | β | β | β | 0.0x |
| Current ratio | 1.4x | 0.7x | 0.6x | 7.8x | 8.8x | 7.0x | 3.9x | 4.2x |
| Quick ratio | 1.3x | 0.7x | 0.6x | 7.7x | 8.7x | 6.9x | 3.8x | 4.2x |
| Capital allocation | ||||||||
| Capex / revenue | 0.6% | 13.3% | β | 15.5% | 13.1% | β | β | β |
| Stock comp / revenue | 22.8% | 249.5% | 212.1% | 42.5% | 21.4% | 8.7% | 0.5% | β |
| Quality scores | ||||||||
| Piotroski F-score | β | 2.0 | 5.0 | 4.0 | 4.0 | 2.0 | 3.0 | 3.0 |
| Altman Z'' | β35.3 | β74.3 | β74.6 | β0.3 | β3.7 | β7.3 | β16.0 | β2.5 |
| Accruals ratio | 17.4% | β95.4% | β117.5% | β17.1% | β9.1% | β47.9% | β27.9% | β1.5% |
Source: SEC EDGAR XBRL filings (CIK 0001789192). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.